(CNCR) Loncar Cancer Immunotherapy - Ratings and Ratios

The Loncar Cancer Immunotherapy ETF (NASDAQ:CNCR), launched in 2023 by Range Fund Holdings, offers exposure to U.S. exchange-listed pharmaceutical and biotechnology companies or ADRs with a market capitalization exceeding $250 million. This ETF is designed to track the performance of its underlying index, focusing on firms involved in cancer immunotherapy, a rapidly advancing field within healthcare. The fund typically invests at least 80% of its assets in the securities comprising the index, ensuring alignment with its investment objective. For more details, visit http://www.LoncarFunds.com.

As of the latest data, CNCR has an average 20-day volume of 3,150 shares, indicating moderate trading activity. The ETFs last price was $10.60, with short-term and long-term moving averages (SMA 20: $11.77, SMA 50: $12.09, SMA 200: $13.88) suggesting recent price weakness. The Average True Range (ATR) of 0.35 reflects moderate volatility. With assets under management (AUM) of $8.64 million, CNCR is a smaller ETF, which may lead to higher sensitivity to market movements.

Over the next three months, CNCRs performance is expected to be influenced by its technical and fundamental outlook. The ETFs current price below its key moving averages (20, 50, and 200-day) may indicate potential short-term challenges. However, the ATR of 0.35 suggests manageable volatility, which could provide opportunities for strategic entry or exit points. Fundamentally, the focus on cancer immunotherapy aligns with a growing sector, potentially offering long-term growth prospects despite the current market conditions.